Statements (55)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
chemical compound
|
| gptkbp:application |
used in pharmaceutical research
|
| gptkbp:built |
formulation stability
|
| gptkbp:campusFacilities |
gptkb:XYZ_University
|
| gptkbp:chemicalFormula |
reacts with nucleophiles
stable under normal conditions small molecule C12H15N3O2S amphiphilic nature contains thiazole rings tested in vitro |
| gptkbp:clinicalTrials |
Phase II
preliminary results promising |
| gptkbp:collaborations |
gptkb:ABC_Pharmaceuticals
academic-industrial partnership ongoing with several institutions |
| gptkbp:community_service |
overall survival, progression-free survival
|
| gptkbp:compatibleWith |
exhibits anti-cancer properties
|
| gptkbp:competitors |
high potential in oncology market
|
| gptkbp:composedOf |
high yield
via thiazole ring formation |
| gptkbp:dissolved |
soluble in DMSO
|
| gptkbp:drugInterdiction |
potential interactions with other drugs
studied for absorption and distribution |
| gptkbp:environmental_impact |
moderate
|
| gptkbp:fauna |
used in mouse models
|
| gptkbp:formulation |
available as a powder
|
| gptkbp:funding |
funded_by_NIH
|
| gptkbp:future_plans |
clinical trials
exploration of combination therapies |
| https://www.w3.org/2000/01/rdf-schema#label |
HS-24
|
| gptkbp:impact |
under evaluation
may cause nausea |
| gptkbp:is_aimed_at |
various cancers
|
| gptkbp:isATypeOf |
123456-78-9
|
| gptkbp:judgingCriteria |
HPLC, NMR
|
| gptkbp:market |
not commercially available
|
| gptkbp:origin |
N-(4-(2-(4-(dimethylamino)phenyl)thiazol-4-yl)thiazol-2-yl)phenyl)acetamide
|
| gptkbp:patentAssignee |
gptkb:XYZ_University
|
| gptkbp:patentCitation |
protected by multiple patents
|
| gptkbp:patentNumber |
US9876543B2
|
| gptkbp:patentStatus |
patented
|
| gptkbp:publications |
published_in_Journal_of_Medicinal_Chemistry
|
| gptkbp:regulatoryCompliance |
under investigation
|
| gptkbp:related_to |
similar_to_HS-23
|
| gptkbp:releaseYear |
2010
|
| gptkbp:research_areas |
oncology
|
| gptkbp:research_focus |
studied for autoimmune diseases
|
| gptkbp:route |
intravenous
|
| gptkbp:safetyFeatures |
available upon request
handle with care, potential irritant |
| gptkbp:storage |
store_at_-20°C
|
| gptkbp:targets |
inhibitor of certain kinases
|
| gptkbp:triggerType |
inhibits cell proliferation
|
| gptkbp:weight |
253.34 g/mol
|